Solitary fibrous tumor of pleura is rare tumors arising from the submesothelial tissue. They differ from the malignant mesotheliomas in having an indolent course, no association with asbestos exposure and a better prognosis than mesotheliomas. Surgery is curative in case of adequately done wide resection. Inadequate resection causes a significantly shorter survival and a high incidence of local recurrence.
{"title":"Solitary Fibrous Tumor Of Pleura: A Rare Tumor","authors":"M. Atul, P. Ashish, Mittal Rajinder","doi":"10.5580/1862","DOIUrl":"https://doi.org/10.5580/1862","url":null,"abstract":"Solitary fibrous tumor of pleura is rare tumors arising from the submesothelial tissue. They differ from the malignant mesotheliomas in having an indolent course, no association with asbestos exposure and a better prognosis than mesotheliomas. Surgery is curative in case of adequately done wide resection. Inadequate resection causes a significantly shorter survival and a high incidence of local recurrence.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74093655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Agnieszka, M. Hill, A. Maraveyas, H. Wasan, F. Lofts
Adenocarcinoma of the pancreas remains one of the most difficult cancers to treat. Raltitrexed, a novel quinazoline analogue, combined with gemcitabine is likely to potentate the anti-cancer effect, as both of those drugs inhibit DNA synthesis via separate metabolic pathway. We report a phase I/II study of increasing dose of gemcitabine with raltitrexed in patients with advanced adenocarcinoma of the pancreas. The study was conducted at three different dose levels with raltitrexed at 3mg/m2 and increasing gemcitabine levels. 24 patients were recruited. Cohort 2 patient developed unexpected toxicity with 58% of patients experiencing haematological toxicity and 29% nausea and vomiting. The majority of patients complained of lethargy and 5 patients reached dose-limiting toxicity. Partial responses were documented in two out of 24 patients (8%), 25% had stable disease and 50% developed progressive disease. We found the combination of raltitrexed and gemcitabine active but poorly tolerated in pancreatic cancer.
{"title":"Phase I/II Study to Investigate the Use of Gemcitabine in Combination with Raltitrexed in Locally Advanced or Metastatic Pancreatic Adenocarcinoma","authors":"Michael Agnieszka, M. Hill, A. Maraveyas, H. Wasan, F. Lofts","doi":"10.5580/250a","DOIUrl":"https://doi.org/10.5580/250a","url":null,"abstract":"Adenocarcinoma of the pancreas remains one of the most difficult cancers to treat. Raltitrexed, a novel quinazoline analogue, combined with gemcitabine is likely to potentate the anti-cancer effect, as both of those drugs inhibit DNA synthesis via separate metabolic pathway. We report a phase I/II study of increasing dose of gemcitabine with raltitrexed in patients with advanced adenocarcinoma of the pancreas. The study was conducted at three different dose levels with raltitrexed at 3mg/m2 and increasing gemcitabine levels. 24 patients were recruited. Cohort 2 patient developed unexpected toxicity with 58% of patients experiencing haematological toxicity and 29% nausea and vomiting. The majority of patients complained of lethargy and 5 patients reached dose-limiting toxicity. Partial responses were documented in two out of 24 patients (8%), 25% had stable disease and 50% developed progressive disease. We found the combination of raltitrexed and gemcitabine active but poorly tolerated in pancreatic cancer.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76231696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cervical cancer is among the most dangerous diseases affecting women worldwide. In Mauritius, it is the second most common cancer in women after breast cancer. During the 1989-1992 period, the incidence of cancer cervix was 20 % of all cancers in females and dropped to 12% during the 1997-2000 period. Over this twelve year period (1989-2000), the mean age of patients with cervical cancer was 56 years. Squamous cell carcinoma was the most common histologic type and the incidence was greatest among the native Mauritian population. A cervical cancer screening program started in Mauritius in the year 2001 and is ongoing.
{"title":"Study Of Cervical Cancers In Mauritius Over A Twelve Years Period (1989-2000) And Role Of Cervical Screening","authors":"N. Jeebun, S. Agnihotri, S. Manraj, B. Purwar","doi":"10.5580/29b1","DOIUrl":"https://doi.org/10.5580/29b1","url":null,"abstract":"Cervical cancer is among the most dangerous diseases affecting women worldwide. In Mauritius, it is the second most common cancer in women after breast cancer. During the 1989-1992 period, the incidence of cancer cervix was 20 % of all cancers in females and dropped to 12% during the 1997-2000 period. Over this twelve year period (1989-2000), the mean age of patients with cervical cancer was 56 years. Squamous cell carcinoma was the most common histologic type and the incidence was greatest among the native Mauritian population. A cervical cancer screening program started in Mauritius in the year 2001 and is ongoing.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85906456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paclitaxel is widely used anti-neoplastic agent. Although peripheral neurotoxicity is a well-known side effect, CNS toxicity related to standard dose paclitaxel is extremely uncommon; probably because paclitaxel does not cross the blood brain barrier. We present a patient with advanced stage ovarian carcinoma who developed acute and spontaneous resolving encephalopathy after standard dose of paclitaxel. The patient did not have brain metastasis, or prior whole brain irradiation, or any type of neurosurgery. Radiological imaging studies showed no abnormalities. Other causes of encephalopathy were rule out. Paclitaxel at standard doses may cause CNS toxicity even in the absence of brain metastasis or disrupted blood brain barrier.
{"title":"Acute Reversible Life-Threatening Encephalopathy Following Conventional Doses Of Paclitaxel Infusion","authors":"Ozlem Yavas, C. Boruban, O. Eren, M. Genc","doi":"10.5580/19bf","DOIUrl":"https://doi.org/10.5580/19bf","url":null,"abstract":"Paclitaxel is widely used anti-neoplastic agent. Although peripheral neurotoxicity is a well-known side effect, CNS toxicity related to standard dose paclitaxel is extremely uncommon; probably because paclitaxel does not cross the blood brain barrier. We present a patient with advanced stage ovarian carcinoma who developed acute and spontaneous resolving encephalopathy after standard dose of paclitaxel. The patient did not have brain metastasis, or prior whole brain irradiation, or any type of neurosurgery. Radiological imaging studies showed no abnormalities. Other causes of encephalopathy were rule out. Paclitaxel at standard doses may cause CNS toxicity even in the absence of brain metastasis or disrupted blood brain barrier.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83253737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Rossi, P. Alessandroni, V. Catalano, P. Giordani, A. Baldelli, S. Fedeli, A. Fedeli, V. Casadei, G. Catalano
This case report concerns an elderly patient with liver and bone metastases of breast cancer successfully treated for two-years with capecitabine as first line chemotherapy without any side effect.
本病例报告涉及一位老年乳腺癌肝骨转移患者，卡培他滨作为一线化疗成功治疗2年，无任何副作用。
{"title":"Durable Response To Capecitabine (Xeloda; Roche) In An Elderly Patient With Liver And Bone Metastases Of Breast Cancer","authors":"D. Rossi, P. Alessandroni, V. Catalano, P. Giordani, A. Baldelli, S. Fedeli, A. Fedeli, V. Casadei, G. Catalano","doi":"10.5580/1752","DOIUrl":"https://doi.org/10.5580/1752","url":null,"abstract":"This case report concerns an elderly patient with liver and bone metastases of breast cancer successfully treated for two-years with capecitabine as first line chemotherapy without any side effect.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81423065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We report a patient with pleural fibrosarcoma recurrent after twelve years post resection, presenting with recurrent falls and loss of consciousness secondary to hypoglycaemia which was never present previously. Her symptoms improved after being treated with diazoxide, an antihypertensive.
{"title":"Hypoglycemia Due To Fibrosarcoma","authors":"S. Kadir, M. Nazer","doi":"10.5580/224f","DOIUrl":"https://doi.org/10.5580/224f","url":null,"abstract":"We report a patient with pleural fibrosarcoma recurrent after twelve years post resection, presenting with recurrent falls and loss of consciousness secondary to hypoglycaemia which was never present previously. Her symptoms improved after being treated with diazoxide, an antihypertensive.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"45 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72581739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ZD 1839 is a novel, low molecular weight, orally active, selective EGFR-tyrosine kinase inhibitor, which in preclinical and phase I studies has showed antitumor activity against cancers expressing EGFR. Phase I-II studies showed that ZD 1839 provides clinically significant antitumor activity in patients with pretreated NSCLC. Subsequently, phase III trials combined ZD1839 and chemotherapy in chemonaive patients with advanced NSCLC. These trials failed to demonstrate a survival advantage with the addition of ZD1839 to standard platinum-based chemotherapy. Some experts have suggested that the concomitant administration of chemotherapy and EGFR tyrosine kinase inhibitors may be antagonistic and that sequential use of these drug is a more appropriate strategy. The molecular mechanisms underlying sensitivity to ZD1839 are unknown, however recent preliminary experiences suggest that EGFR mutations may predict sensitivity to ZD1839. In any case, future trials should be conducted with appropriate correlative studies in diagnostic tumor tissue and a new possible area of clinical investigation include the use of ZD1839 in adjuvant setting.
{"title":"ZD1839 (Gefinitib, Iressa) In Patients With Non Small Cell Lung Cancer: A Real Promise?","authors":"A. Tartarone, G. Romano, R. Ardito, N. Renzo","doi":"10.5580/e95","DOIUrl":"https://doi.org/10.5580/e95","url":null,"abstract":"ZD 1839 is a novel, low molecular weight, orally active, selective EGFR-tyrosine kinase inhibitor, which in preclinical and phase I studies has showed antitumor activity against cancers expressing EGFR. Phase I-II studies showed that ZD 1839 provides clinically significant antitumor activity in patients with pretreated NSCLC. Subsequently, phase III trials combined ZD1839 and chemotherapy in chemonaive patients with advanced NSCLC. These trials failed to demonstrate a survival advantage with the addition of ZD1839 to standard platinum-based chemotherapy. Some experts have suggested that the concomitant administration of chemotherapy and EGFR tyrosine kinase inhibitors may be antagonistic and that sequential use of these drug is a more appropriate strategy. The molecular mechanisms underlying sensitivity to ZD1839 are unknown, however recent preliminary experiences suggest that EGFR mutations may predict sensitivity to ZD1839. In any case, future trials should be conducted with appropriate correlative studies in diagnostic tumor tissue and a new possible area of clinical investigation include the use of ZD1839 in adjuvant setting.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2004-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76530907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. S. Sridhar, D. Sharma, R. Prabhakar, S. Sharma, G. Rath
The incidence of parotid fistula following the surgery has been reported to be about 14%. The parotid fistula can be a very troublesome problem for the patient as it compromises the quality of life. It may result in wound dehiscence, and infection. Though several treatment modalities have been described in the literature but there is no consensus. The various management options include complete parotidectomy, tympanic neurectomy, radiation therapy, pressure dressings, anticholenergics and, of late, local injection of botulinum toxin. Radiation therapy had been in use as early as in 1936, but the number of cases is too scanty to make this as established modality. We describe a case of postparotidectomy fistula successfully treated by external beam radiation therapy.
{"title":"Radiation Therapy for Post Parotidectomy Fistula","authors":"P. S. Sridhar, D. Sharma, R. Prabhakar, S. Sharma, G. Rath","doi":"10.5580/da7","DOIUrl":"https://doi.org/10.5580/da7","url":null,"abstract":"The incidence of parotid fistula following the surgery has been reported to be about 14%. The parotid fistula can be a very troublesome problem for the patient as it compromises the quality of life. It may result in wound dehiscence, and infection. Though several treatment modalities have been described in the literature but there is no consensus. The various management options include complete parotidectomy, tympanic neurectomy, radiation therapy, pressure dressings, anticholenergics and, of late, local injection of botulinum toxin. Radiation therapy had been in use as early as in 1936, but the number of cases is too scanty to make this as established modality. We describe a case of postparotidectomy fistula successfully treated by external beam radiation therapy.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2004-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90052838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: An interaction analysis is used to investigate subgroup effects between breast conserving surgery, radiotherapy and nodal status in early breast cancer. Patients and methods: Women selected from the SEER database, aged 40-69 with non metastasized T1-T2 breast cancer and in whom axillary node dissection was performed. The method uses proportional hazards regression models with interaction terms. Steps of the analysis are detailed. Results: Significant statistical interactions were found between breast conserving surgery, radiotherapy , nodal involvement and T stage. In an integrated factorial presentation of results, patients undergoing breast conserving surgery without radiotherapy were not at survival disadvantage as compared with patients undergoing mastectomy, irrespective of T-stage and irrespective of nodal involvement. However, the addition of radiotherapy to breast conserving surgery was associated with a distinct survival advantage observed in all T stage and all levels of nodal involvement. Conclusion: The analysis of interactions provides a comprehensive view of complex subgroup effects. The formal presentation of results might be useful as a framework to generate hypotheses for further investigations.
{"title":"Statistical Interaction In The Survival Analysis Of Early Breast Cancer Using Registry Data","authors":"Anne-Marie Danzel","doi":"10.5580/531","DOIUrl":"https://doi.org/10.5580/531","url":null,"abstract":"Purpose: An interaction analysis is used to investigate subgroup effects between breast conserving surgery, radiotherapy and nodal status in early breast cancer. Patients and methods: Women selected from the SEER database, aged 40-69 with non metastasized T1-T2 breast cancer and in whom axillary node dissection was performed. The method uses proportional hazards regression models with interaction terms. Steps of the analysis are detailed. Results: Significant statistical interactions were found between breast conserving surgery, radiotherapy , nodal involvement and T stage. In an integrated factorial presentation of results, patients undergoing breast conserving surgery without radiotherapy were not at survival disadvantage as compared with patients undergoing mastectomy, irrespective of T-stage and irrespective of nodal involvement. However, the addition of radiotherapy to breast conserving surgery was associated with a distinct survival advantage observed in all T stage and all levels of nodal involvement. Conclusion: The analysis of interactions provides a comprehensive view of complex subgroup effects. The formal presentation of results might be useful as a framework to generate hypotheses for further investigations.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2004-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75947116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
An inflammatory fibrosarcoma is a rare tumour with a varied biological behaviour, from benign to locally aggressive and occasionally malignant. It generally involves mesentery and retroperitoneal structures, but it rarely can involve the hollow viscera and commonly affects children and young adults. We report a case of inflammatory fibrosarcoma affecting an unusual age group, involving the ileo-caecal junction and ascending colon (a rare site) causing sub-acute intestinal obstruction. We also discuss its surgical management, differential diagnosis and review of current literature. Only a handful of cases have been reported and to the best of our knowledge none of these were from UK.
{"title":"Inflammatory Fibrosarcoma: A Rare Tumour Entity Involving Retroperitoneum And Colon","authors":"B. L. Murthy, D. Mathur, P. Hamal, V. Modgill","doi":"10.5580/fdd","DOIUrl":"https://doi.org/10.5580/fdd","url":null,"abstract":"An inflammatory fibrosarcoma is a rare tumour with a varied biological behaviour, from benign to locally aggressive and occasionally malignant. It generally involves mesentery and retroperitoneal structures, but it rarely can involve the hollow viscera and commonly affects children and young adults. We report a case of inflammatory fibrosarcoma affecting an unusual age group, involving the ileo-caecal junction and ascending colon (a rare site) causing sub-acute intestinal obstruction. We also discuss its surgical management, differential diagnosis and review of current literature. Only a handful of cases have been reported and to the best of our knowledge none of these were from UK.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"5 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2004-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79515318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：